“Increasing Focus on Minimally Invasive Procedures”
The leadless cardiac pacemaker market is experiencing rapid growth, fueled by the trend of minimally invasive procedures gaining preference among both healthcare providers and patients. Leadless pacemakers, such as the Micra AV2 by Medtronic and the AVEIR DR by Abbott, are at the forefront of this shift due to their ability to provide dual-chamber pacing without the need for traditional leads, reducing the risk of infection and complications. This trend is particularly appealing to patients with heart rhythm disorders who are seeking safer, more efficient treatments. For instance, the Micra AV2 offers improved battery life and wireless communication, enhancing the patient experience. In addition, as the global aging population continues to grow, the demand for effective, low-risk treatments for cardiovascular diseases such as atrial fibrillation is expected to rise. This trend underscores the ongoing shift toward advanced, less invasive technologies in the leadless cardiac pacemaker market, positioning it for continued expansion.
